Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-P8 in Primary Sclerosing Cholangitis
NCT06699121Phase 2Recruiting
- Sponsor
- LISCure Biosciences
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of LB-P8 in Primary Sclerosing Cholangitis (PSC), sponsored by LISCure Biosciences. Started Nov 2025; status: recruiting.
02
Drugs
LB-P8
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT06699121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699121.